This article has been updated from a previous version, which incorrectly reported that NimbleGen had licensed and planned to sell Affymetrix's microarrays.
NEW YORK (GenomeWeb News) – Affymetrix has granted NimbleGen a license to patents covering the manufacture, use, and sale of nucleic acid microarrays, the companies said today.
"This license is a major milestone in NimbleGen's evolution as a company, and part of a fundamental expansion of our commercial strategy," said Stan Rose, president and CEO of NimbleGen, in statement. "Our intent is to expand dramatically the ability of scientists to access NimbleGen products and services."
Financial details were not disclosed.